Tuberc Respir Dis.
2008 Aug;65(2):142-146.
Acute Respiratory Distress Syndrome after Topotecan Therapy in a Patient with Small Cell Lung Cancer
- Affiliations
-
- 1Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea. jinhwalee@ewha.ac.kr
- 2Department of Radiology, Ewha Womans University School of Medicine, Seoul, Korea.
Abstract
- Small cell lung cancer is characterized by an aggressive clinical course and a high tendency for early dissemination in spite of a good chemotherapy response. Topotecan is a topoisomerase I inhibitor, and it is used as second-line treatment for small cell lung cancer. The reported dose-limiting adverse reactions to topotecan are mainly hematologic. Yet pulmonary toxicity associated with topotecan is known to be rare. We report here on a case that showed the development of acute respiratory distress syndrome during the 3rd cycle of topotecan chemotherapy in a patient with small cell lung cancer. He developed dyspnea and respiratory failure, and the chest CT scan revealed diffuse ground-glass opacity that was probably due to chemotherapy-related pulmonary toxicity. He finally died of acute respiratory distress syndrome.
Keyword
- Small cell carcinoma; Topotecan; Acute respiratory distress syndrome
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy of Topotecan as a Second-Line Treatment of Small-Cell Lung Cancer in Patients with Refractory and Sensitive Disease: Retrospective Study
- Clinical Study of Topotecan as Second-Line Treatment in Small Cell Lung Cancer
- Clinical Response to Etoposide Plus Carboplatin and Topotecan Chemotherapy in Small Cell Lung Cancer
- Intratracheal Administration of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in a Patient with Acute Respiratory Distress Syndrome
- A case of advanced ovarian cancer which was treated with topotecan after taxol-cisplatin treatment failed
